元（37.8%），其中商业销售收入为14.0 亿元（+49.2%），依沃西和卡度尼利纳入医保目录后销售快速增长。亏损为5.88 亿元（上年同期亏损2.49 亿元），亏损扩大主要由于Summit 股权投资损失计提、研发费用以及股权激励费用的增加。上半年研发费用为7.31 亿元（+23.0%），销售费用6.70 亿元（+29.8%），销售费用率47.8%（-7.1pct）；管理费用1.34 亿元（+...
Source Link元（37.8%），其中商业销售收入为14.0 亿元（+49.2%），依沃西和卡度尼利纳入医保目录后销售快速增长。亏损为5.88 亿元（上年同期亏损2.49 亿元），亏损扩大主要由于Summit 股权投资损失计提、研发费用以及股权激励费用的增加。上半年研发费用为7.31 亿元（+23.0%），销售费用6.70 亿元（+29.8%），销售费用率47.8%（-7.1pct）；管理费用1.34 亿元（+...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.